Pancreatic cancer is the third leading cause of cancer death in the United States, with approximately 66,440 new cases and 51,750 deaths projected in 2026. Five-year relative survival across all stages is less than 13%, with approximately 44% for localized disease and just 3% for distant disease, yet roughly 80% of patients are diagnosed at locally advanced or metastatic stages when curative resection is no longer feasible. New-onset diabetes in adults aged 50 and older carries a ninefold increased risk of pancreatic cancer diagnosis within one year, making this clinical pattern one of the most actionable early recognition signals available to primary care.
AAVBC's Pancreatic Cancer Quick Reference Guide gives clinicians and care teams a practical, evidence-aligned reference covering ICD-10 subsite coding, staging, early recognition signals, diagnostic workup, exocrine insufficiency management, cancer-associated diabetes classification, VTE awareness, comorbidity management, and MEAT documentation standards. Grounded in current NCCN and ASCO guidelines, this guide helps care teams catch pancreatic cancer earlier, document complexity accurately, and keep care coordinated from diagnosis through survivorship.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of pancreatic cancer — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
Pancreatic cancer is the third leading cause of cancer death in the United States, with approximately 66,440 new cases and 51,750 deaths projected in 2026. Five-year relative survival across all stages is less than 13%, with approximately 44% for localized disease and just 3% for distant disease, yet roughly 80% of patients are diagnosed at locally advanced or metastatic stages when curative resection is no longer feasible. New-onset diabetes in adults aged 50 and older carries a ninefold increased risk of pancreatic cancer diagnosis within one year, making this clinical pattern one of the most actionable early recognition signals available to primary care.
AAVBC's Pancreatic Cancer Quick Reference Guide gives clinicians and care teams a practical, evidence-aligned reference covering ICD-10 subsite coding, staging, early recognition signals, diagnostic workup, exocrine insufficiency management, cancer-associated diabetes classification, VTE awareness, comorbidity management, and MEAT documentation standards. Grounded in current NCCN and ASCO guidelines, this guide helps care teams catch pancreatic cancer earlier, document complexity accurately, and keep care coordinated from diagnosis through survivorship.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of pancreatic cancer — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
